47 results on '"Sivarajan K"'
Search Results
2. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial
- Author
-
Cerana, S, Dictar, MO, Bonvehi, P, Tregnaghi, JP, Fein, L, Ashley, D, Singh, M, Hayes, T, Playford, G, Morrissey, O, Thaler, J, Kuehr, T, Greil, R, Pecherstorfer, M, Duck, L, Van Eygen, K, Aoun, M, De Prijck, B, Franke, FA, Barrios, CHE, Mendes, AVA, Serrano, SV, Garcia, RF, Moore, F, Camargo, JFC, Pires, LA, Alves, RS, Radinov, A, Oreshkov, K, Minchev, V, Hubenova, AI, Koynova, T, Ivanov, I, Rabotilova, B, Petrov, PA, Chilingirov, P, Karanikolov, S, Raynov, J, Grimard, D, McNeil, S, Kumar, D, Larratt, LM, Weiss, K, Delage, R, Diaz-Mitoma, FJ, Cano, PO, Couture, F, Carvajal, P, Yepes, A, Torres Ulloa, R, Fardella, P, Caglevic, C, Rojas, C, Orellana, E, Gonzalez, P, Acevedo, A, Galvez, KM, Gonzalez, ME, Franco, S, Restrepo, JG, Rojas, CA, Bonilla, C, Florez, LE, Ospina, AV, Manneh, R, Zorica, R, Vrdoljak, DV, Samarzija, M, Petruzelka, L, Vydra, J, Mayer, J, Cibula, D, Prausova, J, Paulson, G, Ontaneda, M, Palk, K, Vahlberg, A, Rooneem, R, Galtier, F, Postil, D, Lucht, F, Laine, F, Launay, O, Laurichesse, H, Duval, X, Cornely, OA, Camerer, B, Panse, J, Zaiss, M, Derigs, H-G, Menzel, H, Verbeek, M, Georgoulias, V, Mavroudis, D, Anagnostopoulos, A, Terpos, E, Cortes, D, Umanzor, J, Bejarano, S, Galeano, RW, Wong, RSM, Hui, P, Pedrazzoli, P, Ruggeri, L, Aversa, F, Bosi, A, Gentile, G, Rambaldi, A, Contu, A, Marei, L, Abbadi, A, Hayajneh, W, Kattan, J, Farhat, F, Chahine, G, Rutkauskiene, J, Marfil Rivera, LJ, Lopez Chuken, YA, Franco Villarreal, H, Lopez Hernandez, J, Blacklock, H, Lopez, RI, Alvarez, R, Gomez, AM, Quintana, TS, Moreno Larrea, MDC, Zorrilla, SJ, Alarcon, E, Samanez, FCA, Caguioa, PB, Tiangco, BJ, Mora, EM, Betancourt-Garcia, RD, Hallman-Navarro, D, Feliciano-Lopez, LJ, Velez-Cortes, HA, Cabanillas, F, Ganea, DE, Ciuleanu, TE, Ghizdavescu, DG, Miron, L, Cebotaru, CL, Cainap, CI, Anghel, R, Dvorkin, MV, Gladkov, OA, Fadeeva, NV, Kuzmin, AA, Lipatov, ON, Zbarskaya, II, Akhmetzyanov, FS, Litvinov, IV, Afanasyev, BV, Cherenkova, M, Lioznov, D, Lisukov, IA, Smirnova, YA, Kolomietz, S, Halawani, H, Goh, YT, Drgona, L, Chudej, J, Matejkova, M, Reckova, M, Rapoport, BL, Szpak, WM, Malan, DR, Jonas, N, Jung, CW, Lee, DG, Yoon, SS, Lopez Jimenez, J, Duran Martinez, I, Rodriguez Moreno, JF, Solano Vercet, C, de la Camara, R, Batlle Massana, M, Yeh, S-P, Chen, C-Y, Chou, H-H, Tsai, C-M, Chiu, C-H, Siritanaratkul, N, Norasetthada, L, Sriuranpong, V, Seetalarom, K, Akan, H, Dane, F, Ozcan, MA, Ozsan, GH, Kalayoglu Besisik, SF, Cagatay, A, Yalcin, S, Peniket, A, Mullan, SR, Dakhil, KM, Sivarajan, K, Suh, JJ-G, Sehgal, A, Marquez, F, Gomez, EG, Mullane, MR, Skinner, WL, Behrens, RJ, Trevarthe, DR, Mazurczak, MA, Lambiase, EA, Vidal, CA, Anac, SY, Rodrigues, GA, Baltz, B, Boccia, R, Wertheim, MS, Holladay, CS, Zenk, D, Fusselman, W, Wade III, JL, Jaslowsk, AJ, Keegan, J, Robinson, MO, Go, RS, Farnen, J, Amin, B, Jurgens, D, Risi, GF, Jr, Beatty, PG, Naqvi, T, Parshad, S, Hansen, VL, Ahmed, M, Steen, PD, Badarinath, S, Dekker, A, Scouros, MA, Young, DE, Graydon Harker, W, Kendall, SD, Citron, ML, Chedid, S, Posada, JG, Jr, Gupta, MK, Rafiyath, S, Buechler-Price, J, Sreenivasappa, S, Chay, CH, Burke, JM, Young, SE, Mahmood, A, Kugler, JW, Gerstner, G, Fuloria, J, Belman, ND, Geller, R, Nieva, J, Whittenberger, BP, Wong, BMY, Cescon, TP, Abesada-Terk, G, Jr, Guarino, MJ, Zweibach, A, Ibrahim, EN, Takahashi, G, Garrison, MA, Mowat, RB, Choi, BS, Oliff, IA, Singh, J, Guter, KA, Ayrons, K, Rowland, KM, Noga, SJ, Rao, SB, Columbie, A, Nualart, MT, Cecchi, GR, Campos, LT, Mohebtash, M, Flores, MR, Rothstein-Rubin, R, O'Connor, BM, Soori, G, Knapp, M, Miranda, FG, Goodgame, BW, Kassem, M, Belani, R, Sharma, S, Ortiz, T, Sonneborn, HL, Markowitz, AB, Wilbur, D, Meiri, E, Koo, VS, Jhangiani, HS, Wong, L, Sanani, S, Lawrence, SJ, Jones, CM, Murray, C, Papageorgiou, C, Gurtler, JS, Ascensao, JL, Venigalla, ML, D'Andrea, M, De Las Casas, C, Haile, DJ, Qazi, FU, Santander, JL, Thomas, MR, Rao, VP, Craig, M, Garg, RJ, Robles, R, Lyons, RM, Stegemoller, RK, Goel, S, Garg, S, Lowry, P, Lynch, C, Lash, B, Repka, T, Baker, J, Goueli, BS, Campbell, TC, Van Echo, DA, Lee, YJ, Reyes, EA, Senecal, FM, Donnelly, G, Byeff, P, Weiss, R, Reid, T, Roeland, E, Goel, A, Prow, DM, Brandt, DS, Kaplan, HG, Payne, JE, Boeckh, MG, Rosen, PJ, Mena, RR, Khan, R, Betts, RF, Sharp, SA, Morrison, VA, Fitz-Patrick, D, Congdon, J, Erickson, N, Abbasi, R, Henderson, S, Mehdi, A, Wos, EJ, Rehmus, E, Beltzer, L, Tamayo, RA, Mahmood, T, Reboli, AC, Moore, A, Brown, JM, Cruz, J, Quick, DP, Potz, JL, Kotz, KW, Hutchins, M, Chowhan, NM, Devabhaktuni, YD, Braly, P, Berenguer, RA, Shambaugh, SC, O'Rourke, TJ, Conkright, WA, Winkler, CF, Addo, FEK, Duic, JP, High, KP, Kutner, ME, Collins, R, Carrizosa, DR, Perry, DJ, Kailath, E, Rosen, N, Sotolongo, R, Shoham, S, Chen, T, Mullane, Kathleen M, Morrison, Vicki A, Camacho, Luis H, Arvin, Ann, McNeil, Shelly A, Durrand, Jessie, Campbell, Bernadette, Su, Shu-Chih, Chan, Ivan S F, Parrino, Janie, Kaplan, Susan S, Popmihajlov, Zoran, and Annunziato, Paula W
- Published
- 2019
- Full Text
- View/download PDF
3. Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation
- Author
-
Harrison T. Muturi, Hilda E. Ghadieh, Suman Asalla, Sumona G. Lester, Getachew D. Belew, Sobia Zaidi, Raziyeh Abdolahipour, Abhishek P. Shrestha, Agnes O. Portuphy, Hannah L. Stankus, Raghd Abu Helal, Stefaan Verhulst, Sergio Duarte, Ali Zarrinpar, Leo A. van Grunsven, Scott L. Friedman, Robert F. Schwabe, Terry D. Hinds, Jr., Sivarajan Kumarasamy, and Sonia M. Najjar
- Subjects
Hepatic fibrosis ,Inflammation ,Hepatic steatosis ,Stellate cell proliferation ,Retinoic acid ,Internal medicine ,RC31-1245 - Abstract
Objectives: Hepatic CEACAM1 expression declines with advanced hepatic fibrosis stage in patients with metabolic dysfunction-associated steatohepatitis (MASH). Global and hepatocyte-specific deletions of Ceacam1 impair insulin clearance to cause hepatic insulin resistance and steatosis. They also cause hepatic inflammation and fibrosis, a condition characterized by excessive collagen production from activated hepatic stellate cells (HSCs). Given the positive effect of PPARγ on CEACAM1 transcription and on HSCs quiescence, the current studies investigated whether CEACAM1 loss from HSCs causes their activation. Methods: We examined whether lentiviral shRNA-mediated CEACAM1 donwregulation (KD-LX2) activates cultured human LX2 stellate cells. We also generated LratCre + Cc1fl/fl mutants with conditional Ceacam1 deletion in HSCs and characterized their MASH phenotype. Media transfer experiments were employed to examine whether media from mutant human and murine HSCs activate their wild-type counterparts. Results: LratCre + Cc1fl/fl mutants displayed hepatic inflammation and fibrosis but without insulin resistance or hepatic steatosis. Their HSCs, like KD-LX2 cells, underwent myofibroblastic transformation and their media activated wild-type HSCs. This was inhibited by nicotinic acid treatment which blunted the release of IL-6 and fatty acids, both of which activate the epidermal growth factor receptor (EGFR) tyrosine kinase. Gefitinib inhibition of EGFR and its downstream NF-κB/IL-6/STAT3 inflammatory and MAPK-proliferation pathways also blunted HSCs activation in the absence of CEACAM1. Conclusions: Loss of CEACAM1 in HSCs provoked their myofibroblastic transformation in the absence of insulin resistance and hepatic steatosis. This response is mediated by autocrine HSCs activation of the EGFR pathway that amplifies inflammation and proliferation.
- Published
- 2024
- Full Text
- View/download PDF
4. Analysis of Specific Control Strategies using Simulation for D-STATCOM in Three-phase Systems
- Author
-
Sivarajan K N and Dr. Jasmin E A
- Published
- 2021
5. PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)
- Author
-
Mahalingam, D., Patel, M., Sachdev, J., Hart, L., Halama, N., Ramanathan, R., Sarantopoulos, J., Liu, X., Yazji, S., Jäger, D., Adib, D., Kerschbaumer, R., Yoon, M., Manzur, G., Starodub, A., Sivarajan, K., Wertheim, M., Thambi, P., Jones, M., Goel, S., Nemunaitis, J., and Tsimberidou, A.
- Published
- 2016
- Full Text
- View/download PDF
6. Phase shift control and controller area network assisted proportional resonant control for grid integration of single phase voltage source inverters
- Author
-
Nirmal, S., primary, Sivarajan, K. N., additional, and Jasmin, E. A., additional
- Published
- 2021
- Full Text
- View/download PDF
7. Power Quality problems And Mitigation Using D-STATCOM With H-bridge topology In Solar PV Integrated Distribution System
- Author
-
Jasmin Ea, Sivarajan K N, and B. Jayanand
- Subjects
Distribution system ,Three-phase ,Computer science ,Photovoltaic system ,Power quality ,Topology (electrical circuits) ,AC power ,H bridge ,Topology ,Power (physics) - Abstract
This paper presents Power Quality (PQ) problems and mitigation using D-STATCOM with H-Bridge topology in solar Photo Voltaic (PV) integrated distribution system. D-STATCOM solve current related issues of networks. Three-phase, four-wire, 400 V and 50 Hz system is selected as distribution source. The power quality improvement along with PV integration is intended by using D-STATCOM. Another goal is to design the components of shunt compensator for a PV integrated three phase distribution system. The Custom Power Device (CPD) is 50 kVA rated and uses battery storage system. Economical and robust design is ensured. Various loads were connected in the system for simulation studies and results were analyzed and validated.
- Published
- 2020
8. Age-associated deficit of mitochondrial oxidative phosphorylation in skeletal muscle: Role of carnitine and lipoic acid
- Author
-
Kumaran, S., Panneerselvam, Kavin S., Shila, S., Sivarajan, K., and Panneerselvam, C.
- Published
- 2005
- Full Text
- View/download PDF
9. Power Quality problems And Mitigation Using D-STATCOM With H-bridge topology In Solar PV Integrated Distribution System
- Author
-
N, Sivarajan K, primary, EA, Jasmin, additional, and Jayanand, B, additional
- Published
- 2020
- Full Text
- View/download PDF
10. A Microbiological Study of Anterior Nasal Packs in Epistaxis
- Author
-
Gupta, Abhay, Agrawal, S. R., Sivarajan, K., and Gupta, Vineeta
- Published
- 1999
- Full Text
- View/download PDF
11. Restoration of PITPNA in Type 2 diabetic human islets reverses pancreatic beta-cell dysfunction
- Author
-
Yu-Te Yeh, Chandan Sona, Xin Yan, Yunxiao Li, Adrija Pathak, Mark I. McDermott, Zhigang Xie, Liangwen Liu, Anoop Arunagiri, Yuting Wang, Amaury Cazenave-Gassiot, Adhideb Ghosh, Ferdinand von Meyenn, Sivarajan Kumarasamy, Sonia M. Najjar, Shiqi Jia, Markus R. Wenk, Alexis Traynor-Kaplan, Peter Arvan, Sebastian Barg, Vytas A. Bankaitis, and Matthew N. Poy
- Subjects
Science - Abstract
Abstract Defects in insulin processing and granule maturation are linked to pancreatic beta-cell failure during type 2 diabetes (T2D). Phosphatidylinositol transfer protein alpha (PITPNA) stimulates activity of phosphatidylinositol (PtdIns) 4-OH kinase to produce sufficient PtdIns-4-phosphate (PtdIns-4-P) in the trans-Golgi network to promote insulin granule maturation. PITPNA in beta-cells of T2D human subjects is markedly reduced suggesting its depletion accompanies beta-cell dysfunction. Conditional deletion of Pitpna in the beta-cells of Ins-Cre, Pitpna flox/flox mice leads to hyperglycemia resulting from decreasing glucose-stimulated insulin secretion (GSIS) and reducing pancreatic beta-cell mass. Furthermore, PITPNA silencing in human islets confirms its role in PtdIns-4-P synthesis and leads to impaired insulin granule maturation and docking, GSIS, and proinsulin processing with evidence of ER stress. Restoration of PITPNA in islets of T2D human subjects reverses these beta-cell defects and identify PITPNA as a critical target linked to beta-cell failure in T2D.
- Published
- 2023
- Full Text
- View/download PDF
12. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
- Author
-
Vergote, I. Scambia, G. O'Malley, D.M. Van Calster, B. Park, S.-Y. del Campo, J.M. Meier, W. Bamias, A. Colombo, N. Wenham, R.M. Covens, A. Marth, C. Raza Mirza, M. Kroep, J.R. Ma, H. Pickett, C.A. Monk, B.J. Park, S.Y. Song, Y.S. Makarova, Y. Trinidad, J. Ngan, H.Y.S. Aravantinos, G. Nam, J.-H. Gorbunova, V. Krikunova, L. Bae, D.-S. Arija, J.A.A. Mirza, M.R. Zamagni, C. Papandreou, C. Raspagliesi, F. Lisyanskaya, A. Benzaquen, A.O. Tognon, G. Ortega, E. Herraez, A.C. Buscema, J. Green, A. Burger, R. Sakaeva, D. Sanchez, A.R. Ghamande, S. King, L. Petru, E. Peen, U. Takeuchi, S. Ushijima, K. Martin, A.G. Kamelle, S. Carney, M. Forget, F. Bentley, J. Sehouli, J. Zola, P. Kato, H. Fadeeva, N. Gotovkin, E. Vladimirov, V. Marin, M.R. Alia, E.G. Shahin, M. Bhoola, S. Tewari, K. Anderson, D. Honhon, B. Pelgrims, J.G. Oza, A. Jimenez, J.G.-D. Hansen, V. Benjamin, I. Renard, V. Van den Bulck, H. Haenle, C. Koumakis, G. Yokota, H. Popov, V. Bradley, W. Wenham, R. Reid, R. McNamara, D. Friedman, R. Barlin, J. Spirtos, N. Chapman, J. Sevelda, P. Huizing, M. Lamot, C. Goffin, F. Hondt, L.D. Covens, A. Spadafora, S. Rautenberg, B. Reimer, T. Möbus, V. Hilpert, F. Gropp-Meier, M. Savarese, A. Pignata, S. Verderame, F. Mizuno, M. Takano, H. Ottevanger, P. Velasco, A.P. Palacio-Vazquez, I. Law, A. McIntyre, K. Teneriello, M. Fields, A. Lentz, S. Street, D. Schwartz, B. Mannel, R. Lim, P. Pulaski, H. Janni, W. Zorr, A. Karck, U. Cheng, A.C.K. Sorio, R. Gridelli, C. Aoki, D. Oishi, T. Hirashima, Y. Boere, I. Ferrer, E.F. Braly, P. Wilks, S. Lee, C. Schilder, J. Veljovich, D. Secord, A. Davis, K. Rojas-Espaillat, L. Lele, S. DePasquale, S. Squatrito, R. Schauer, C. Dirix, L. Vuylsteke, P. Joosens, E. Provencher, D. Lueck, H.-J. Hein, A. Burges, A. Canzler, U. Park-Simon, T.-W. Griesinger, F. Gadducci, A. Alabiso, O. Okamoto, A. Sawasaki, T. Saito, T. Ibañez, A.H. Calomeni, C. Spillman, M. Choksi, J. Taylor, N. Muller, C. Moore, D. DiSilvestro, P. Cunningham, M. Rose, P. Oppelt, P. Verhoeven, D. Graas, M.-P. Ghatage, P. Tonkin, K. Kurzeder, C. Schnappauf, B. Müller, V. Schmalzrie, H. Kalofonos, H. Bruzzone, M. Kroep, J. Diaz, C.C. Garcia, J.M. Polo, S.H. Garrison, M. Rocconi, R. Andrews, S. Bristow, R. McHale, M. Basil, J. Houck III, W. Bell, M. Cosin, J. Modesitt, S. Kendrick, J. Wade III, J. Wong, C. Evans, A. Buekers, T. Vanderkwaak, T. Ferriss, J. Darus, C. DAndre, S. Higgins, R. Monk, B. Bakkum-Gamez, J. DeMars, L. Van Le, L. Puls, L. Trehan, S. LaPolla, J. Michelson, E.D. Merchant, J. Peterson, C. Reid, G. Seago, D. Zweizig, S. Gajewski, W. Panwalkar, A. Leikermoser, R. Bogner, G. Debruyne, P. D'hondt, R. Berteloot, P. Kerger, J. Biagi, J. Castonguay, V. Welch, S. Muhic, A. Heubner, M. Grischke, E.-M. Rack, B. Fleisch, M. Lordick, F. Pectasides, D. Ho, W.M. Selvaggi, L. Vasquez, F.M. Villanueva, W.O.B. Alavez, A.M. Kessels, L. Bertran, A.S. Fernandez, C.M. Fabregat, M.B. Del Prete, S. Elkas, J. Cecchi, G. Kumar, P. Huh, W. Messing, M. Karimi, M. Kelley, A. Edraki, B. Mutch, D. Leiserowitz, G. Anderson, J. Lentz, S. Chambers, S. Morris, R. Waggoner, S. Gordon, A. Method, M. Johnson, P. Lord, R. Drake, J. Sivarajan, K. Midathada, M. Rice, K. Wadsworth, T. Pavelka, J. Edwards, R. Miller, D.S. Ford, P.L. Hurteau, J. Bender, D. Schimp, V. Creasman, W. Lerner, R. Chamberlain, D. Kueck, A. McDonald, J. Malad, S. Robinson-Bennett, B. Davidson, S. Krivak, T. Lestingi, T. Arango, H. Berard, P. Finkelstein, K. Gaur, R. Krasner, C. Ueland, F. Talmage, L. Yamada, S. Sutton, G. Potkul, R. Prasad-Hayes, M. Osborne, J. Celano, P. Thigpen, J. Sharma, S. Schilder, R. Tammela, J. Kemeny, M. Brown, A. Eisenhauer, E. Williams, J. Rowland, K. Nahum, K. Burke, J. Dar, Z. Fleming, N. Gibb, R. Guirguis, A. Herzog, T. John, V. Kumar, S. Kamat, A. Kassar, M. Leitao, M. Levine, L. Mendez, L. Patel, D. Berry, E. Warshal, D. Wolf, J. Zarwan, C. Collins, Y. Spitzer, G. Miller, B. Einstein, M. TRINOVA-3/ENGOT-ov2/GOG-3001 investigators
- Abstract
Background: Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2, improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial. Methods: TRINOVA-3, a multicentre, multinational, phase 3, double-blind study, was done at 206 investigational sites (hospitals and cancer centres)in 14 countries. Eligible patients were aged 18 years or older with biopsy-confirmed International Federation of Gynecology and Obstetrics (FIGO)stage III to IV epithelial ovarian, primary peritoneal, or fallopian tube cancers, and an ECOG performance status of 0 or 1. Eligible patients were randomly assigned (2:1)using a permuted block method (block size of six patients)to receive six cycles of paclitaxel (175 mg/m2)and carboplatin (area under the serum concentration-time curve 5 or 6)every 3 weeks, plus weekly intravenous trebananib 15 mg/kg or placebo. Maintenance therapy with trebananib or placebo continued for up to 18 additional months. The primary endpoint was progression-free survival, as assessed by the investigators, in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01493505, and is complete. Findings: Between Jan 30, 2012, and Feb 25, 2014, 1164 patients were screened and 1015 eligible patients were randomly allocated to treatment (678 to trebananib and 337 to placebo). After a median follow-up of 27·4 months (IQR 17·7–34·2), 626 patients had progression-free survival events (405 [60%]of 678 in the trebananib group and 221 [66%]of 337 in the placebo group). Median progression-free survival did not differ between the trebananib group (15·9 months [15·0–17·6])and the placebo group (15·0 months [12·6–16·1])groups (hazard ratio 0·93 [95% CI 0·79–1·09]; p=0·36). 512 (76%)of 675 patients in the trebananib group and 237 (71%)of 336 in the placebo group had grade 3 or worse treatment-emergent adverse events; of which the most common events were neutropenia (trebananib 238 [35%]vs placebo 126 [38%])anaemia (76 [11%]vs 40 [12%]), and leucopenia (81 [12%]vs 35 [10%]). 269 (40%)patients in the trebananib group and 104 (31%)in the placebo group had serious adverse events. Two fatal adverse events in the trebananib group were considered related to trebananib, paclitaxel, and carboplatin (lung infection and neutropenic colitis); two were considered to be related to paclitaxel and carboplatin (general physical health deterioration and platelet count decreased). No treatment-related fatal adverse events occurred in the placebo group. Interpretation: Trebananib plus carboplatin and paclitaxel did not improve progression-free survival as first-line treatment for advanced ovarian cancer. The combination of trebananib plus carboplatin and paclitaxel did not produce new safety signals. These results show that trebananib in combination with carboplatin and paclitaxel is minimally effective in this patient population. Funding: Amgen. © 2019 Elsevier Ltd
- Published
- 2019
13. Cell versus message level performances in ATM networks
- Author
-
Cidon, I., Guérin, R., Khamisy, A., and Sivarajan, K. N.
- Published
- 1996
- Full Text
- View/download PDF
14. The effect of traffic shaping in efficiently providing end-to-end performance guarantees
- Author
-
Georgiadis, L., Guérin, R., Peris, V., and Sivarajan, K. N.
- Published
- 1996
- Full Text
- View/download PDF
15. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial
- Author
-
Mullane, Kathleen M, primary, Morrison, Vicki A, additional, Camacho, Luis H, additional, Arvin, Ann, additional, McNeil, Shelly A, additional, Durrand, Jessie, additional, Campbell, Bernadette, additional, Su, Shu-Chih, additional, Chan, Ivan S F, additional, Parrino, Janie, additional, Kaplan, Susan S, additional, Popmihajlov, Zoran, additional, Annunziato, Paula W, additional, Cerana, S, additional, Dictar, MO, additional, Bonvehi, P, additional, Tregnaghi, JP, additional, Fein, L, additional, Ashley, D, additional, Singh, M, additional, Hayes, T, additional, Playford, G, additional, Morrissey, O, additional, Thaler, J, additional, Kuehr, T, additional, Greil, R, additional, Pecherstorfer, M, additional, Duck, L, additional, Van Eygen, K, additional, Aoun, M, additional, De Prijck, B, additional, Franke, FA, additional, Barrios, CHE, additional, Mendes, AVA, additional, Serrano, SV, additional, Garcia, RF, additional, Moore, F, additional, Camargo, JFC, additional, Pires, LA, additional, Alves, RS, additional, Radinov, A, additional, Oreshkov, K, additional, Minchev, V, additional, Hubenova, AI, additional, Koynova, T, additional, Ivanov, I, additional, Rabotilova, B, additional, Petrov, PA, additional, Chilingirov, P, additional, Karanikolov, S, additional, Raynov, J, additional, Grimard, D, additional, McNeil, S, additional, Kumar, D, additional, Larratt, LM, additional, Weiss, K, additional, Delage, R, additional, Diaz-Mitoma, FJ, additional, Cano, PO, additional, Couture, F, additional, Carvajal, P, additional, Yepes, A, additional, Torres Ulloa, R, additional, Fardella, P, additional, Caglevic, C, additional, Rojas, C, additional, Orellana, E, additional, Gonzalez, P, additional, Acevedo, A, additional, Galvez, KM, additional, Gonzalez, ME, additional, Franco, S, additional, Restrepo, JG, additional, Rojas, CA, additional, Bonilla, C, additional, Florez, LE, additional, Ospina, AV, additional, Manneh, R, additional, Zorica, R, additional, Vrdoljak, DV, additional, Samarzija, M, additional, Petruzelka, L, additional, Vydra, J, additional, Mayer, J, additional, Cibula, D, additional, Prausova, J, additional, Paulson, G, additional, Ontaneda, M, additional, Palk, K, additional, Vahlberg, A, additional, Rooneem, R, additional, Galtier, F, additional, Postil, D, additional, Lucht, F, additional, Laine, F, additional, Launay, O, additional, Laurichesse, H, additional, Duval, X, additional, Cornely, OA, additional, Camerer, B, additional, Panse, J, additional, Zaiss, M, additional, Derigs, H-G, additional, Menzel, H, additional, Verbeek, M, additional, Georgoulias, V, additional, Mavroudis, D, additional, Anagnostopoulos, A, additional, Terpos, E, additional, Cortes, D, additional, Umanzor, J, additional, Bejarano, S, additional, Galeano, RW, additional, Wong, RSM, additional, Hui, P, additional, Pedrazzoli, P, additional, Ruggeri, L, additional, Aversa, F, additional, Bosi, A, additional, Gentile, G, additional, Rambaldi, A, additional, Contu, A, additional, Marei, L, additional, Abbadi, A, additional, Hayajneh, W, additional, Kattan, J, additional, Farhat, F, additional, Chahine, G, additional, Rutkauskiene, J, additional, Marfil Rivera, LJ, additional, Lopez Chuken, YA, additional, Franco Villarreal, H, additional, Lopez Hernandez, J, additional, Blacklock, H, additional, Lopez, RI, additional, Alvarez, R, additional, Gomez, AM, additional, Quintana, TS, additional, Moreno Larrea, MDC, additional, Zorrilla, SJ, additional, Alarcon, E, additional, Samanez, FCA, additional, Caguioa, PB, additional, Tiangco, BJ, additional, Mora, EM, additional, Betancourt-Garcia, RD, additional, Hallman-Navarro, D, additional, Feliciano-Lopez, LJ, additional, Velez-Cortes, HA, additional, Cabanillas, F, additional, Ganea, DE, additional, Ciuleanu, TE, additional, Ghizdavescu, DG, additional, Miron, L, additional, Cebotaru, CL, additional, Cainap, CI, additional, Anghel, R, additional, Dvorkin, MV, additional, Gladkov, OA, additional, Fadeeva, NV, additional, Kuzmin, AA, additional, Lipatov, ON, additional, Zbarskaya, II, additional, Akhmetzyanov, FS, additional, Litvinov, IV, additional, Afanasyev, BV, additional, Cherenkova, M, additional, Lioznov, D, additional, Lisukov, IA, additional, Smirnova, YA, additional, Kolomietz, S, additional, Halawani, H, additional, Goh, YT, additional, Drgona, L, additional, Chudej, J, additional, Matejkova, M, additional, Reckova, M, additional, Rapoport, BL, additional, Szpak, WM, additional, Malan, DR, additional, Jonas, N, additional, Jung, CW, additional, Lee, DG, additional, Yoon, SS, additional, Lopez Jimenez, J, additional, Duran Martinez, I, additional, Rodriguez Moreno, JF, additional, Solano Vercet, C, additional, de la Camara, R, additional, Batlle Massana, M, additional, Yeh, S-P, additional, Chen, C-Y, additional, Chou, H-H, additional, Tsai, C-M, additional, Chiu, C-H, additional, Siritanaratkul, N, additional, Norasetthada, L, additional, Sriuranpong, V, additional, Seetalarom, K, additional, Akan, H, additional, Dane, F, additional, Ozcan, MA, additional, Ozsan, GH, additional, Kalayoglu Besisik, SF, additional, Cagatay, A, additional, Yalcin, S, additional, Peniket, A, additional, Mullan, SR, additional, Dakhil, KM, additional, Sivarajan, K, additional, Suh, JJ-G, additional, Sehgal, A, additional, Marquez, F, additional, Gomez, EG, additional, Mullane, MR, additional, Skinner, WL, additional, Behrens, RJ, additional, Trevarthe, DR, additional, Mazurczak, MA, additional, Lambiase, EA, additional, Vidal, CA, additional, Anac, SY, additional, Rodrigues, GA, additional, Baltz, B, additional, Boccia, R, additional, Wertheim, MS, additional, Holladay, CS, additional, Zenk, D, additional, Fusselman, W, additional, Wade III, JL, additional, Jaslowsk, AJ, additional, Keegan, J, additional, Robinson, MO, additional, Go, RS, additional, Farnen, J, additional, Amin, B, additional, Jurgens, D, additional, Risi, GF, additional, Beatty, PG, additional, Naqvi, T, additional, Parshad, S, additional, Hansen, VL, additional, Ahmed, M, additional, Steen, PD, additional, Badarinath, S, additional, Dekker, A, additional, Scouros, MA, additional, Young, DE, additional, Graydon Harker, W, additional, Kendall, SD, additional, Citron, ML, additional, Chedid, S, additional, Posada, JG, additional, Gupta, MK, additional, Rafiyath, S, additional, Buechler-Price, J, additional, Sreenivasappa, S, additional, Chay, CH, additional, Burke, JM, additional, Young, SE, additional, Mahmood, A, additional, Kugler, JW, additional, Gerstner, G, additional, Fuloria, J, additional, Belman, ND, additional, Geller, R, additional, Nieva, J, additional, Whittenberger, BP, additional, Wong, BMY, additional, Cescon, TP, additional, Abesada-Terk, G, additional, Guarino, MJ, additional, Zweibach, A, additional, Ibrahim, EN, additional, Takahashi, G, additional, Garrison, MA, additional, Mowat, RB, additional, Choi, BS, additional, Oliff, IA, additional, Singh, J, additional, Guter, KA, additional, Ayrons, K, additional, Rowland, KM, additional, Noga, SJ, additional, Rao, SB, additional, Columbie, A, additional, Nualart, MT, additional, Cecchi, GR, additional, Campos, LT, additional, Mohebtash, M, additional, Flores, MR, additional, Rothstein-Rubin, R, additional, O'Connor, BM, additional, Soori, G, additional, Knapp, M, additional, Miranda, FG, additional, Goodgame, BW, additional, Kassem, M, additional, Belani, R, additional, Sharma, S, additional, Ortiz, T, additional, Sonneborn, HL, additional, Markowitz, AB, additional, Wilbur, D, additional, Meiri, E, additional, Koo, VS, additional, Jhangiani, HS, additional, Wong, L, additional, Sanani, S, additional, Lawrence, SJ, additional, Jones, CM, additional, Murray, C, additional, Papageorgiou, C, additional, Gurtler, JS, additional, Ascensao, JL, additional, Venigalla, ML, additional, D'Andrea, M, additional, De Las Casas, C, additional, Haile, DJ, additional, Qazi, FU, additional, Santander, JL, additional, Thomas, MR, additional, Rao, VP, additional, Craig, M, additional, Garg, RJ, additional, Robles, R, additional, Lyons, RM, additional, Stegemoller, RK, additional, Goel, S, additional, Garg, S, additional, Lowry, P, additional, Lynch, C, additional, Lash, B, additional, Repka, T, additional, Baker, J, additional, Goueli, BS, additional, Campbell, TC, additional, Van Echo, DA, additional, Lee, YJ, additional, Reyes, EA, additional, Senecal, FM, additional, Donnelly, G, additional, Byeff, P, additional, Weiss, R, additional, Reid, T, additional, Roeland, E, additional, Goel, A, additional, Prow, DM, additional, Brandt, DS, additional, Kaplan, HG, additional, Payne, JE, additional, Boeckh, MG, additional, Rosen, PJ, additional, Mena, RR, additional, Khan, R, additional, Betts, RF, additional, Sharp, SA, additional, Morrison, VA, additional, Fitz-Patrick, D, additional, Congdon, J, additional, Erickson, N, additional, Abbasi, R, additional, Henderson, S, additional, Mehdi, A, additional, Wos, EJ, additional, Rehmus, E, additional, Beltzer, L, additional, Tamayo, RA, additional, Mahmood, T, additional, Reboli, AC, additional, Moore, A, additional, Brown, JM, additional, Cruz, J, additional, Quick, DP, additional, Potz, JL, additional, Kotz, KW, additional, Hutchins, M, additional, Chowhan, NM, additional, Devabhaktuni, YD, additional, Braly, P, additional, Berenguer, RA, additional, Shambaugh, SC, additional, O'Rourke, TJ, additional, Conkright, WA, additional, Winkler, CF, additional, Addo, FEK, additional, Duic, JP, additional, High, KP, additional, Kutner, ME, additional, Collins, R, additional, Carrizosa, DR, additional, Perry, DJ, additional, Kailath, E, additional, Rosen, N, additional, Sotolongo, R, additional, Shoham, S, additional, and Chen, T, additional
- Published
- 2019
- Full Text
- View/download PDF
16. Chronic suppurative otitis media—A bacteriological study
- Author
-
Nandy, Atanu, Mallya, P. S., and Sivarajan, K.
- Published
- 1991
- Full Text
- View/download PDF
17. Comparative Analysis of Communication Assisted Grid Synchronization Methods in Microgrids.
- Author
-
S., Nirmal, N., Sivarajan K., A., Jasmin E., and Ahamed, T. P. Imthias
- Abstract
Microgrid, an entity of localized power generation, is capable of being connected to the traditional centralized power grid. Stability, power quality, and protection are the major topics of concern for optimal operation of microgrids. The critical element in grid synchronization is the current control strategy meeting the standards for connection to the grid. Communication assisted grid synchronization methods employing optimal current control strategy need to be applied to attain both voltage and frequency stabilities after the interconnection. The objective is to simulate, analyze, and compare communication assisted current control techniques namely natural reference frame control and proportional reference frame control techniques in three-phase grid connected converters. The best control strategy is selected to achieve secure and smooth synchronization of the microgrid. The conventional control techniques have been modified to achieve load compensation, power quality, and stability. Two microsources are synchronized to the ac distribution system, wherein the phase template of the grid is passed through the reliable, fast, and fault tolerant controller area network. The performance of the two schemes is compared based on the power quality standards, stability, computational burden, and implementation difficulties. The test system is simulated in a KVASER configured CAN network in MATLAB software. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Steady state error elimination and harmonic compensation using proportional resonant current controller in grid-tied DC microgrids
- Author
-
Nirmal, S, primary, Sivarajan, K. N, additional, Jasmin, E A, additional, Nandakumar, M, additional, and Jayanand, B, additional
- Published
- 2018
- Full Text
- View/download PDF
19. Modified current control technique for grid synchronization in voltage source converters
- Author
-
Nirmal, S, primary, Sivarajan, K. N., additional, Jasmin, E A, additional, Nandakumar, M, additional, and Jayanand, B, additional
- Published
- 2017
- Full Text
- View/download PDF
20. Intrarenal Dopaminergic System Is Dysregulated in SS-Resp18mutant Rats
- Author
-
Usman M. Ashraf, Ealla Atari, Fawaz Alasmari, Harshal Waghulde, Vikash Kumar, Youssef Sari, Sonia M. Najjar, Pedro A. Jose, and Sivarajan Kumarasamy
- Subjects
Resp18 ,kidney ,blood pressure ,dopamine ,Dahl salt-sensitive rats ,Biology (General) ,QH301-705.5 - Abstract
The genetic and molecular basis of developing high blood pressure and renal disease are not well known. Resp18mutant Dahl salt-sensitive (SS-Resp18mutant) rats fed a 2% NaCl diet for six weeks have high blood pressure, increased renal fibrosis, and decreased mean survival time. Impairment of the dopaminergic system also leads to hypertension that involves renal and non-renal mechanisms. Deletion of any of the five dopamine receptors may lead to salt-sensitive hypertension. Therefore, we investigated the interaction between Resp18 and renal dopamine in SS-Resp18mutant and Dahl salt-sensitive (SS) rats. We found that SS-Resp18mutant rats had vascular dysfunction, as evidenced by a decrease in vasorelaxation in response to sodium nitroprusside. The pressure–natriuresis curve in SS-Resp18mutant rats was shifted down and to the right of SS rats. SS-Resp18mutant rats had decreased glomerular filtration rate and dopamine receptor subtypes, D1R and D5R. Renal dopamine levels were decreased, but urinary dopamine levels were increased, which may be the consequence of increased renal dopamine production, followed by secretion into the tubular lumen. The increased renal dopamine production in SS-Resp18mutant rats in vivo was substantiated by the increased dopamine production in renal proximal tubule cells treated with L-DOPA. Overall, our study provides evidence that targeted disruption of the Resp18 locus in the SS rat dysregulates the renal dopaminergic system.
- Published
- 2023
- Full Text
- View/download PDF
21. Regulation of Insulin Clearance by Non-Esterified Fatty Acids
- Author
-
Sonia M. Najjar, Raziyeh Abdolahipour, Hilda E. Ghadieh, Marziyeh Salehi Jahromi, John A. Najjar, Basil A. M. Abuamreh, Sobia Zaidi, Sivarajan Kumarasamy, and Harrison T. Muturi
- Subjects
insulin resistance ,insulin clearance ,non-esterified fatty acids ,hyperinsulinemia ,non-alcoholic fatty liver disease (NAFLD) ,Biology (General) ,QH301-705.5 - Abstract
Insulin stores lipid in adipocytes and prevents lipolysis and the release of non-esterified fatty acids (NEFA). Excessive release of NEFA during sustained energy supply and increase in abdominal adiposity trigger systemic insulin resistance, including in the liver, a major site of insulin clearance. This causes a reduction in insulin clearance as a compensatory mechanism to insulin resistance in obesity. On the other hand, reduced insulin clearance in the liver can cause chronic hyperinsulinemia, followed by downregulation of insulin receptor and insulin resistance. Delineating the cause–effect relationship between reduced insulin clearance and insulin resistance has been complicated by the fact that insulin action and clearance are mechanistically linked to insulin binding to its receptors. This review discusses how NEFA mobilization contributes to the reciprocal relationship between insulin resistance and reduced hepatic insulin clearance, and how this may be implicated in the pathogenesis of non-alcoholic fatty liver disease.
- Published
- 2022
- Full Text
- View/download PDF
22. Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
- Author
-
Schwartzberg, L.S., primary, Tauer, K., additional, Atkins, J., additional, Sivarajan, K., additional, Patel, V., additional, Bastos, B., additional, Langer, C., additional, Socinski, M.A., additional, and Spigel, D.R., additional
- Published
- 2012
- Full Text
- View/download PDF
23. A Synthesis of Pseudoconhydrine and Its Epimer via Hydroformylation and Dihydroxylation
- Author
-
Bates, Roderick W., primary, Sivarajan, K., additional, and Straub, Bernd F., additional
- Published
- 2011
- Full Text
- View/download PDF
24. SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs
- Author
-
Raed Shalaby, Jacobus P. Petzer, Anél Petzer, Usman M. Ashraf, Ealla Atari, Fawaz Alasmari, Sivarajan Kumarasamy, Youssef Sari, and Ashraf Khalil
- Subjects
monoamine oxidase ,chalcone ,reversibility ,dopamine ,mrna ,Therapeutics. Pharmacology ,RM1-950 - Abstract
The present study describes the synthesis of a series of 22 chalcone analogs. These compounds were evaluated as potential human MAO-A and MAO-B inhibitors. The compounds showed varied selectivity against the two isoforms. The IC50 values were found to be in the micromolar to submicromolar range. The Ki values of compound 16 were determined to be 0.047 and 0.020 μM for the inhibition of MAO-A and MAO-B, respectively. Dialysis of enzyme-inhibitor mixtures indicated a reversible competitive mode of inhibition. Most of the synthesized chalcone analogs showed a better selectivity toward MAO-B. However, introducing of 2,4,6-trimethoxy substituents on ring B shifted the selectivity toward MAO-A. In addition, we investigated the molecular mechanism of MAO-B inhibition by selected chalcone analogs. Our results revealed that these selected chalcone analogs increased dopamine levels in the rat hepatoma (H4IIE) cells and decreased the relative mRNA expression of the MAO-B enzyme.
- Published
- 2019
- Full Text
- View/download PDF
25. Performance limits for FDMA cellular systems described by hypergraphs
- Author
-
McEliece, R. J. and Sivarajan, K. N.
- Abstract
The authors present some preliminary material about hypergraphs, including a discussion of what they call random hypergraph multicolorings, a notion which is central to the analysis of frequency-assignment algorithms. They show that for any frequency-assignment algorithm, the carried traffic function must satisfy T(r)⩽T_0(r), where T_0(r) is a simple function that can be computed by linear programming. They give an asymptotic analysis of a class of 'fixed' frequency-assignment algorithms, and show that in the limit as n→∞, these algorithms achieve carried traffic functions that are at least as large as T_1( r), another simple function that can be computed by linear programming. They show that T_0(r)=T_1(r). This common value, denoted by T_(H,p)(r) is the function referred to above. They also describe some of the most important properties of the function TH,p(r), and identify the 'most favorable' traffic patterns for a given hypergraph H.
- Published
- 1991
26. Combined efficacies of dl-alpha-lipoic acid and meso 2,3 dimercaptosuccinic acid against arsenic induced toxicity in antioxidant systems of rats
- Author
-
Kokilavani, V., Devi, M.A., Sivarajan, K., and Panneerselvam, C.
- Subjects
Antioxidants -- Health aspects ,Succimer -- Drug therapy -- Health aspects ,Health ,Drug therapy ,Health aspects - Abstract
Combined efficacies of dl-alpha-lipoic acid and meso 2,3 dimercaptosuccinic acid against arsenic induced toxicity in antioxidant systems of rats. Kokilavani V, Devi MA, Sivarajan K, Panneerselvam C. Toxicol Lett 2005 [...]
- Published
- 2005
27. Efficacy of levo carnitine and alpha lipoic acid in ameliorating the decline in mitochondrial enzymes during aging
- Author
-
Savitha, S., primary, Sivarajan, K., additional, Haripriya, D., additional, Kokilavani, V., additional, and Panneerselvam, C., additional
- Published
- 2005
- Full Text
- View/download PDF
28. Renal Fibrosis Is Significantly Attenuated Following Targeted Disruption of Cd40 in Experimental Renal Ischemia
- Author
-
Shungang Zhang, Joshua D. Breidenbach, Fatimah K. Khalaf, Prabhatchandra R. Dube, Chrysan J. Mohammed, Apurva Lad, Stanislaw Stepkowski, Terry D. Hinds, Sivarajan Kumarasamy, Andrew Kleinhenz, Jiang Tian, Deepak Malhotra, David J. Kennedy, Christopher J. Cooper, and Steven T. Haller
- Subjects
CD40 ,renal fibrosis ,renal ischemia ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Renal artery stenosis is a common cause of renal ischemia, contributing to the development of chronic kidney disease. To investigate the role of local CD40 expression in renal artery stenosis, Goldblatt 2‐kidney 1‐clip surgery was performed on hypertensive Dahl salt‐sensitive rats (S rats) and genetically modified S rats in which CD40 function is abolished (Cd40mutant). Methods and Results Four weeks following the 2‐kidney 1‐clip procedure, Cd40mutant rats demonstrated significantly reduced blood pressure and renal fibrosis in the ischemic kidneys compared with S rat controls. Similarly, disruption of Cd40 resulted in reduced 24‐hour urinary protein excretion in Cd40mutant rats versus S rat controls (46.2±1.9 versus 118.4±5.3 mg/24 h; P
- Published
- 2020
- Full Text
- View/download PDF
29. Multihop lightwave networks based on De Bruijn graphs
- Author
-
Sivarajan, K., primary and Ramaswami, R., additional
- Published
- 1991
- Full Text
- View/download PDF
30. Automated analysis of small RNA datasets with RAPID
- Author
-
Sivarajan Karunanithi, Martin Simon, and Marcel H. Schulz
- Subjects
Comparative analysis ,sRNA tool ,Automated sRNA analysis ,sRNA ,Small RNA analysis ,Computational sRNA analysis ,Medicine ,Biology (General) ,QH301-705.5 - Abstract
Understanding the role of short-interfering RNA (siRNA) in diverse biological processes is of current interest and often approached through small RNA sequencing. However, analysis of these datasets is difficult due to the complexity of biological RNA processing pathways, which differ between species. Several properties like strand specificity, length distribution, and distribution of soft-clipped bases are few parameters known to guide researchers in understanding the role of siRNAs. We present RAPID, a generic eukaryotic siRNA analysis pipeline, which captures information inherent in the datasets and automatically produces numerous visualizations as user-friendly HTML reports, covering multiple categories required for siRNA analysis. RAPID also facilitates an automated comparison of multiple datasets, with one of the normalization techniques dedicated for siRNA knockdown analysis, and integrates differential expression analysis using DESeq2. Availability and Implementation RAPID is available under MIT license at https://github.com/SchulzLab/RAPID. We recommend using it as a conda environment available from https://anaconda.org/bioconda/rapid
- Published
- 2019
- Full Text
- View/download PDF
31. Application of Lactophenol Cotton Blue for Identification and Preservation of Intestinal Parasites in Faecal Wet Mounts.
- Author
-
KHUBNANI, HARISH, SIVARAJAN, K., and KHUBNANI, ASHA H.
- Published
- 1998
32. Study of Cryptosporidiosis in a Rural Area of Maharashtra.
- Author
-
KHUBNANI, HARISH, SIVARAJAN, K., and KHUBNANI, ASHA H.
- Published
- 1997
33. Characterization of a Long Non-Coding RNA, the Antisense RNA of Na/K-ATPase α1 in Human Kidney Cells
- Author
-
Xiaoming Fan, Usman M. Ashraf, Christopher A. Drummond, Huilin Shi, Xiaolu Zhang, Sivarajan Kumarasamy, and Jiang Tian
- Subjects
long non-coding RNA ,ATP1A1-AS1 ,Na/K-ATPase ,Src ,signaling transduction ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Non-coding RNAs are important regulators of protein-coding genes. The current study characterized an antisense long non-coding RNA, ATP1A1-AS1, which is located on the opposite strand of the Na/K-ATPase α1 gene. Our results show that four splice variants are expressed in human adult kidney cells (HK2 cells) and embryonic kidney cells (HEK293 cells). These variants can be detected in both cytosol and nuclear fractions. We also found that the inhibition of DNA methylation has a differential effect on the expression of ATP1A1-AS1 and its sense gene. To investigate the physiological role of this antisense gene, we overexpressed the ATP1A1-AS1 transcripts, and examined their effect on Na/K-ATPase expression and related signaling function in human kidney cells. The results showed that overexpression of the ATP1A1-AS1-203 transcript in HK2 cells reduced the Na/K-ATPase α1 (ATP1A1) gene expression by approximately 20% (p < 0.05), while reducing the Na/K-ATPase α1 protein synthesis by approximately 22% (p < 0.05). Importantly, overexpression of the antisense RNA transcript attenuated ouabain-induced Src activation in HK2 cells. It also inhibited the cell proliferation and potentiated ouabain-induced cell death. These results demonstrate that the ATP1A1-AS1 gene is a moderate negative regulator of Na/K-ATPase α1, and can modulate Na/K-ATPase-related signaling pathways in human kidney cells.
- Published
- 2018
- Full Text
- View/download PDF
34. Cholera Epidemic in and Around Loni a Rural Area in Western Maharashtra.
- Author
-
Gujrathi, U. P., Sivarajan, K., and Kulkarni, S. G.
- Published
- 2000
35. Barrett esophagus.
- Author
-
Mullai, N, Sivarajan, K M, and Shiomoto, G
- Subjects
- *
BULIMIA , *ESOPHAGEAL tumors , *GASTROESOPHAGEAL reflux , *BARRETT'S esophagus , *DISEASE complications - Published
- 1991
- Full Text
- View/download PDF
36. Deciphering the impact of Acinetobacter baumannii on human health, and exploration of natural compounds as efflux pump inhibitors to treat multidrug resistance.
- Author
-
Sivarajan K, Ravindhiran R, Sekar JN, Murugesan R, Chidambaram K, and Dhandapani K
- Subjects
- Humans, Membrane Transport Proteins metabolism, Bacterial Proteins metabolism, Bacterial Proteins antagonists & inhibitors, Bacterial Proteins genetics, Biological Products pharmacology, Acinetobacter baumannii drug effects, Acinetobacter baumannii metabolism, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents pharmacology, Acinetobacter Infections drug therapy, Acinetobacter Infections microbiology
- Abstract
Acinetobacter baumannii is an ESKAPE pathogen and threatens human health by generating infections with high fatality rates. A. baumannii leads to a spectrum of infections such as skin and wound infections, endocarditis, meningitis pneumonia, septicaemia and urinary tract infections. Recently, strains of A. baumannii have emerged as multidrug-resistant (MDR), meaning they are resistant to at least three different classes of antibiotics. MDR development is primarily intensified by widespread antibiotic misuse and inadequate stewardship. The World Health Organization (WHO) declared A. baumannii a precarious MDR species. A. baumannii maintains the MDR phenotype via a diverse array of antimicrobial metabolite-hydrolysing enzymes, efflux of antibiotics, impermeability and antibiotic target modification, thereby complicating treatment. Hence, a deeper understanding of the resistance mechanisms employed by MDR A. baumannii can give possible approaches to treat antimicrobial resistance. Resistance-nodulation-cell division (RND) efflux pumps have been identified as the key contributors to MDR determinants, owing to their capacity to force a broad spectrum of chemical substances out of the bacterial cell. Though synthetic inhibitors have been reported previously, their efficacy and safety are of debate. As resistance-modifying agents, phytochemicals are ideal choices. These natural compounds could eliminate the bacteria or interact with pathogenicity events and reduce the bacteria's ability to evolve resistance. This review aims to highlight the mechanism behind the multidrug resistance in A. baumannii and elucidate the utility of natural compounds as efflux pump inhibitors to deal with the infections caused by A. baumannii .
- Published
- 2024
- Full Text
- View/download PDF
37. Pillar[ n ]arenes in the Fight against Biofilms: Current Developments and Future Perspectives.
- Author
-
Jothi Nayaki S, Roja A, Ravindhiran R, Sivarajan K, Arunachalam M, and Dhandapani K
- Subjects
- Humans, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Cations pharmacology, Biofilms, Bacterial Infections drug therapy
- Abstract
The global surge in bacterial infections, compounded by the alarming escalation of drug-resistant strains, has evolved into a critical public health crisis. Among the challenges posed, biofilms stand out due to their formidable resistance to conventional antibiotics. This review delves into the burgeoning potential of pillar[ n ]arenes, distinctive macrocyclic host molecules, as promising anti-biofilm agents. The review is structured into two main sections, each dedicated to exploring distinct facets of pillar[ n ]arene applications. The first section scrutinizes functionalized pillar[ n ]arenes with a particular emphasis on cationic derivatives. This analysis reveals their significant efficacy in inhibiting biofilm formation, underscoring the pivotal role of specific chemical attributes in combating microbial communities. The second section of the review shifts its focus to inclusion complexes, elucidating how pillar[ n ]arenes serve as encapsulation platforms for antibiotics. This encapsulation enhances the stability of antibiotics and enables a controlled release, thereby amplifying their antibacterial activity. The examination of inclusion complexes provides valuable insights into the potential synergy between pillar[ n ]arenes and traditional antibiotics, offering a novel avenue for overcoming biofilm resistance. This comprehensive review highlights the escalating global threat of bacterial infections and the urgent need for innovative strategies to counteract drug-resistant biofilms. The unique properties of pillar[ n ]arenes, both as functionalized molecules and as inclusion complex hosts, position them as promising candidates in the quest for effective anti-biofilm agents. The exploration of their distinct mechanisms opens new avenues for research and development in the ongoing battle against bacterial infections and biofilm-related health challenges.
- Published
- 2024
- Full Text
- View/download PDF
38. Listeria monocytogenes an Emerging Pathogen: a Comprehensive Overview on Listeriosis, Virulence Determinants, Detection, and Anti-Listerial Interventions.
- Author
-
Ravindhiran R, Sivarajan K, Sekar JN, Murugesan R, and Dhandapani K
- Subjects
- Animals, Humans, Virulence, Food Microbiology, Virulence Factors genetics, Listeria monocytogenes genetics, Listeria, Listeriosis diagnosis, Listeriosis epidemiology, Listeriosis microbiology
- Abstract
Listeria monocytogenes, the third most deleterious zoonotic pathogen, is a major causative agent of animal and human listeriosis, an infection related to the consumption of contaminated food products. Even though, this pathogen has been responsible for the outbreaks of foodborne infections in the early 1980s, the major outbreaks have been reported during the past two decades. Listeriosis infection in the host is a rare but life-threatening disease with major public health and economic implications. Extensive reports on listeriosis outbreaks are associated with milk and milk products, meat and meat products, and fresh produce. This bacterium can adapt to any environmental and stress conditions, making it a prime causative agent for major foodborne diseases. The pathogen could survive an antibiotic treatment and persist in the host cell, thereby escaping the standard diagnostic practices. The current review strives to provide concise information on the epidemiology, serotypes, and pathogenesis of the L. monocytogenes to decipher the knowledge on the endurance of the pathogen inside the host and food products as a vehicle for Listeria contaminations. In addition, various detection methods for Listeria species from food samples and frontline regimens of L. monocytogenes treatment have also been discussed., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
39. Multimodal mapping and monitoring is beneficial during awake craniotomy for intra-cranial tumours: results of a dual centre retrospective study.
- Author
-
Manfield J, Waqar M, Mercer D, Ehsan S, Bambrough J, Ibrahim N, Sivarajan K, Bailey M, Karabatsou K, Coope D, Ponnusamy A, Phang I, and D'Urso PI
- Subjects
- Humans, Middle Aged, Retrospective Studies, Wakefulness, Craniotomy methods, Seizures etiology, Seizures surgery, Brain Mapping methods, Brain Neoplasms surgery, Brain Neoplasms pathology, Intraoperative Neurophysiological Monitoring
- Abstract
Background: The combination of awake craniotomy with multimodal neurophysiological mapping and monitoring in intra-axial tumour resection is not well described, but may have theoretical benefits which we sought to investigate., Methods: All patients undergoing awake craniotomy for tumour resection with cortical and/or subcortical stimulation together with one or more of electrocorticography (ECoG/EEG), motor or somatosensory evoked potentials were identified from the operative records of two surgeons at two centres over a 5 year period. Patient, operative and outcome data were collated. Statistical analysis was performed to evaluate factors predictive of intra-operative seizures and surgical outcomes., Results: 83 patients with a median age 50 years (18-80 years) were included. 80% had gliomas (37% low grade) and 13% metastases. Cortical mapping was negative in 35% (language areas) and 24% (motor areas). Complete or near total resection was achieved in 80% with 5% severe long-term neurological deficits. Negative cortical mapping was combined with positive subcortical mapping in 42% with no significant difference in extent of resection rates to patients undergoing positive cortical mapping ( p = 0.95). Awake mapping could not be completed in 14%, but with no compromise to extent of resection ( p = 0.55) or complication rates ( p = 0.09). Intraoperative seizures occurred in 11% and were significantly associated with intra-operative EEG spikes ( p = 0.003)., Conclusions: Awake multi-modal monitoring is a safe and well tolerated technique. It provides preservation of extent of resection and clinical outcomes in cases of aborted awake craniotomy. Negative cortical mapping in combination with positive subcortical mapping was also shown to be safe, although not hitherto well described. Electrocorticography further enables the differentiation of seizure activity from true positive mapping, and the successful treatment of spikes prior to full clinical seizures occurring.
- Published
- 2023
- Full Text
- View/download PDF
40. Pharmacokinetic profile of sarcin and thionin from Aspergillus giganteus and in vitro validation against human fungal pathogen.
- Author
-
Ravindhiran R, Krishnamurthy R, Sivarajan K, Sekar JN, Chidambaram K, Alqahtani AM, and Dhandapani K
- Subjects
- Antifungal Agents pharmacology, Aspergillus, Aspergillus fumigatus metabolism, Fungal Proteins metabolism, Humans, Aspergillosis drug therapy, Aspergillosis microbiology, Chitinases metabolism, Thionins metabolism, Thionins pharmacology
- Abstract
Fungal infections are more predominant in agricultural and clinical fields. Aspergillosis caused by Aspergillus fumigatus leads to respiratory failure in patients along with various illnesses. Due to the limitation of antifungal therapy and antifungal drugs, there is an emergence to develop efficient antifungal compounds (AFCs) from natural sources to cure and prevent fungal infections. The present study deals with the investigation of the mechanism of the active compounds from Aspergillus giganteus against aspergillosis. Primarily, the bioavailability and toxicological properties of antifungal proteins such as, sarcin, thionin, chitinase and their derivatives have proved the efficiency of pharmacokinetic properties of selected compounds. Molecular interactions of selected compounds from A. giganteus with the virulence proteins of A. fumigatus (UDP-N-acetylglucosamine pyrophosphorylase, N-myristoyl transferase and Chitinase) have exhibited a good glide score and druggable nature of the AFCs. The antagonistic potential of AFCs on the pathogen was confirmed by SEM analysis where the shrunken and damaged spores of AFCs treated pathogen were observed. The integrity of A. fumigatus cell membrane and nuclear membrane treated with AFCs were analyzed by determining the release of cellular materials. The effective concentration of AFCs was found to be 250 µg/ml (P<0.0001). The GC-MS profiling has revealed the volatile bioactive metabolites present in A. giganteus. Further, interaction studies might provide more information on the synergism activity with the non-volatile metabolites which leads to the development of novel drugs for the treatment of aspergillosis., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
41. Fungal Infections as an Uprising Threat to Human Health: Chemosensitization of Fungal Pathogens With AFP From Aspergillus giganteus .
- Author
-
Dhandapani K, Sivarajan K, Ravindhiran R, and Sekar JN
- Subjects
- Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Aspergillus, Fungal Proteins metabolism, Fungi metabolism, Humans, alpha-Fetoproteins pharmacology, alpha-Fetoproteins therapeutic use, Fungicides, Industrial pharmacology, Mycoses drug therapy, Mycoses microbiology
- Abstract
Occurrence and intensity of systemic invasive fungal infections have significantly risen in recent decades with large amount of mortality and morbidity rates at global level. Treatment therapy lies on the current antifungal interventions and are often limited due to the emergence of resistance to antifungal agents. Chemosensitization of fungal strains to the conventional antimycotic drugs are of growing concern. Current antifungal drugs often have been reported with poor activity and side effects to the host and have a few number of targets to manifest their efficacy on the pathogens. Indiscriminately, the aforementioned issues have been easily resolved by the development of new intervention strategies. One such approach is to employ combinational therapy that has exhibited a great level of inhibitions than that of a single compound. Chemosensitization of pathogenic mycoses to commercial antifungal drugs could be drastically enhanced by co-application of chemosensitizers along with the conventional drugs. Chemosensitizers could address the resistance mechanisms evolved in the pathogenic fungi and targeting the system to make the organism susceptible to commercially and clinically proven antifungal drugs. However, this strategy has not been overreached to the greater level, but it needs much attention to fight against not only with the pathogen but combat the resistance mechanisms of pathogens to drugs. Natural compounds including plant compounds and microbial proteins act as potential chemosensitizers to break the resistance in mycoses. Aspergillus giganteus , a filamentous fungus, is known to produce a cysteine rich extracellular protein called as antifungal protein (AFP). AFP has shown enhanced efficacy against several filamentous and non-filamentous fungal pathogens. On the basis of the reported studies on its targeted potential against pathogenic mycoses, AFP would be fabricated as a good chemosensitizer to augment the fungicidal efficacy of commercial antimycotic drugs. This paper reviews on breakthrough in the discovery of antifungal drugs along with the resistance patterns of mycoses to commercial drugs followed by the current intervention strategies applied to augment the fungicidal potential of drugs., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Dhandapani, Sivarajan, Ravindhiran and Sekar.)
- Published
- 2022
- Full Text
- View/download PDF
42. Age-dependent upregulation of p53 and cytochrome c release and susceptibility to apoptosis in skeletal muscle fiber of aged rats: role of carnitine and lipoic acid.
- Author
-
Tamilselvan J, Jayaraman G, Sivarajan K, and Panneerselvam C
- Subjects
- Aging genetics, Animals, Apoptosis drug effects, Apoptotic Protease-Activating Factor 1 genetics, Base Sequence, Caspase 3 genetics, Caspase 3 metabolism, Caspase 9 genetics, Cytochromes c pharmacology, DNA Primers genetics, Dietary Supplements, Free Radicals metabolism, Genes, p53, Male, Muscle Fibers, Skeletal drug effects, Muscle Fibers, Skeletal metabolism, Muscle Fibers, Skeletal pathology, Muscle, Skeletal drug effects, Proto-Oncogene Proteins c-bcl-2 metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Rats, Wistar, Up-Regulation, Aging metabolism, Aging pathology, Carnitine pharmacology, Cytochromes c metabolism, Muscle, Skeletal cytology, Muscle, Skeletal metabolism, Thioctic Acid pharmacology, Tumor Suppressor Protein p53 metabolism
- Abstract
Mitochondrial dysfunction has been implicated in the regulation of myofiber loss during aging, possibly by apoptotic pathways. However, the mitochondrial-mediated pathway of apoptosis by cytochrome c in skeletal muscle remains ambiguous. To understand this, we have studied the upstream and downstream events of cytochrome c release, and assessed the efficacy of carnitine and lipoic acid cosupplementation. The results show that elevated levels of cytosolic cytochrome c activate apoptosis in aged rats, and was confirmed further by in vitro caspase-3 assay. Interestingly, the exogenous addition of cytochrome c results in a much higher increase of caspase-3 activity in aged treated rats than age-matched control rats, strongly suggesting that cytochrome c is a limiting factor for caspase-3 activation in the cytosol. Carnitine and lipoic acid supplement decreased apoptosis in aged rats by maintaining mitochondrial membrane integrity and thereby preventing further loss of cytochrome c in vivo. Furthermore, the upregulation of p53 observed in aged rats is attributed to the loss of outer mitochondrial membrane integrity and subsequent release of cytochrome c through BH3-only proteins. In conclusion, the p53-dependent activation of the mitochondrial-cytochrome c pathway of apoptosis in the present study suggests the existence of cross talk between mitochondria and nucleus. However, the exact molecular mechanism remains to be explored. Oral supplements of carnitine and lipoic acid play an antiapoptotic role in aged rat skeletal muscle by protecting mitochondrial membrane integrity.
- Published
- 2007
- Full Text
- View/download PDF
43. Cytochrome c oxidase rather than cytochrome c is a major determinant of mitochondrial respiratory capacity in skeletal muscle of aged rats: role of carnitine and lipoic acid.
- Author
-
Tamilselvan J, Sivarajan K, Anusuyadevi M, and Panneerselvam C
- Subjects
- Administration, Oral, Animals, Carnitine chemistry, Carnitine metabolism, Carnitine pharmacology, Cell Nucleus metabolism, Muscle, Skeletal metabolism, Oxidation-Reduction, Oxygen Consumption, Rats, Rats, Wistar, Thioctic Acid pharmacology, Aging, Caspases metabolism, Cytochromes c chemistry, Electron Transport Complex IV metabolism, Mitochondria metabolism
- Abstract
The release of mitochondrial cytochrome c followed by activation of caspase cascade has been reported with aging in various tissues, whereas little is known about the caspase-independent pathway involved in mitochondrial dysfunction. To determine the functional impact of cytochrome c loss on mitochondrial respiratory capacity, we monitored NADH redox transitions and oxygen consumption in isolated skeletal muscle mitochondria of 4- and 24-month-old rats in the presence and absence of exogenous cytochrome c; and assessed the efficacy of cosupplementation of carnitine and lipoic acid on age-related alteration in mitochondrial respiration. The loss of mitochondrial cytochrome c with age was accompanied with alteration in respiratory transition, which in turn was not rescued by exogenous addition of cytochrome c to isolated mitochondria. The analysis of mitochondrial and nuclear-encoded cytochrome c oxidase subunits suggests that the decreased levels of cytochrome c oxidase may be attributed for the irresponsiveness to exogenously added cytochrome c on mitochondrial respiratory transitions, possibly through reduction of upstream electron carriers. Oral supplementation of carnitine and lipoic acid to aged rats help to maintaining the mitochondrial oxidative capacity by regulating the release of cytochrome c and improves cytochrome c oxidase transcript levels. Thus, carnitine and lipoic acid supplementation prevents the loss of cytochrome c and their associated decline in cytochrome c oxidase activity; thereby, effectively attenuating any putative decrease in cellular energy and redox status with age.
- Published
- 2007
- Full Text
- View/download PDF
44. Combined efficacies of DL-alpha-lipoic acid and meso 2,3 dimercaptosuccinic acid against arsenic induced toxicity in antioxidant systems of rats.
- Author
-
Kokilavani V, Devi MA, Sivarajan K, and Panneerselvam C
- Subjects
- Animals, Antidotes pharmacology, Arsenites metabolism, Ascorbic Acid metabolism, Catalase metabolism, Glutathione metabolism, Glutathione Peroxidase metabolism, Kidney enzymology, Kidney metabolism, Lipid Peroxides metabolism, Liver enzymology, Liver metabolism, Male, Rats, Rats, Wistar, Reactive Oxygen Species metabolism, Superoxide Dismutase metabolism, alpha-Tocopherol metabolism, Antioxidants pharmacology, Arsenites toxicity, Chelating Agents pharmacology, Succimer pharmacology, Thioctic Acid pharmacology
- Abstract
Health hazards caused by heavy metals have become a great concern to the population. Arsenic as an environmental agent is considered to be a toxic substance due to its carcinogenic potential in humans. Since arsenic compounds might exert their toxicity by the generation of reactive oxygen species, we have evaluated the effect of both DL-alpha-lipoic acid (LA) and meso 2,3 dimercapto succinic acid (DMSA) on the antioxidants and lipid peroxidation in arsenic treated rats. The objective of the study was to determine whether DL-alpha-lipoic acid and meso 2,3 dimercapto succinic acid could rehabitate antioxidant depletion and damage to biomolecules in protection against oxidative insults. A significant increase in the levels of reactive oxygen species formation and lipid peroxidation and decrease in the activities of antioxidant enzymes were observed in arsenic exposed rats. Supplementation of DL-alpha-lipoic acid and meso 2,3 dimercapto succinic acid to arsenic fed rats significantly increased the activities of superoxide dismutase, catalase, glutathione peroxidase with elevation in the levels of reduced glutathione, total sulfhydryl, ascorbic acid and alpha-tocopherol. In addition, significant decrease in the levels of reactive oxygen species formation and lipid peroxidation was also observed in our study. From our results, we conclude that DL-alpha-lipoic acid and meso 2,3 dimercapto succinic acid play a synergistic role in decreasing arsenic induced oxidative damage by elevating the antioxidant status in liver and kidney.
- Published
- 2005
- Full Text
- View/download PDF
45. Merkel cell tumor in pregnancy. A case report.
- Author
-
Kuppuswami N, Sivarajan KM, Hussein L, Ray VH, and Freese UE
- Subjects
- Adult, Biopsy, Carcinoma, Merkel Cell diagnostic imaging, Carcinoma, Merkel Cell pathology, Female, Humans, Pregnancy, Pregnancy Complications, Neoplastic diagnostic imaging, Pregnancy Complications, Neoplastic pathology, Radiography, Skin Neoplasms diagnostic imaging, Skin Neoplasms pathology, Spinal Neoplasms diagnostic imaging, Spinal Neoplasms radiotherapy, Ultrasonography, Carcinoma, Merkel Cell diagnosis, Pregnancy Complications, Neoplastic diagnosis, Skin Neoplasms diagnosis, Spinal Neoplasms secondary
- Abstract
A Merkel cell tumor occurred in a young, pregnant woman. The patient delivered prematurely, and the infant died of prematurity. The patient died within two years of the diagnosis.
- Published
- 1991
46. Surgical excision in stage I-II small-cell lung cancer.
- Author
-
Sivarajan KM
- Subjects
- Combined Modality Therapy, Humans, Neoplasm Staging, Prognosis, Carcinoma, Small Cell surgery, Lung Neoplasms surgery
- Published
- 1987
47. Gross hematuria from renal metastasis.
- Author
-
Sivarajan KM, Samuel J, Shiomoto G, and Rhee HL
- Subjects
- Autopsy, Biopsy, Carcinoma, Squamous Cell complications, Carcinoma, Squamous Cell diagnosis, Female, Humans, Kidney Neoplasms complications, Liver Neoplasms secondary, Middle Aged, Carcinoma, Squamous Cell secondary, Esophageal Neoplasms diagnosis, Hematuria etiology, Kidney Neoplasms secondary
- Published
- 1988
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.